Testing carbocisteine for fatty liver disease in adults with NAFLD
Tests carbocisteine, with diet and exercise, in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06863376, who can take part
Where in Egypt
- Tanta UnuversityTanta, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT06863376
- Record updated
- 4 May 2026
- Original description
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.Read full original descriptionShow less
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
Inclusion: Either male or female adult patients (>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography.
Exclusion: Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis; patients suffering from chronic kidney disease, and hyper/hypoparathyroidism; Hypersensitivity to carbocistiene; Pregnant and/or lactating women; Excessive alcohol use (defined as an average alcohol intake > 30 g per day in men and > 20 g per day in women).